Therapy Areas: Autoimmune
Alpine Immune Sciences to Host R and D Day
12 September 2022 - - US-based clinical-stage immunotherapy company Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will host an R and D Day featuring clinical data presentations on ALPN-303, a potentially best-in-class dual B cell cytokine antagonist being developed for the treatment of B cell mediated inflammatory and autoimmune diseases, and davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor in development for the treatment of cancer, the company said.

The event will also feature presentations by two leading experts, Vibeke Strand, MD, Biopharmaceutical Consultant and Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine, and Katy E. Beckermann, MD, PhD, Assistant Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, who will review the current treatment landscape as well as the potential role for new treatment options in lupus and renal cell carcinoma, respectively.

R and D Day Event will be held on Monday, September 12, 5:00 pm to 6:30 pm ET.

Event registration will be available through the Alpine Immune Sciences website at https: //ir.alpineimmunesciences.com/events. An archive of the presentation will be accessible after the event through the Alpine Immune Sciences website.

Alpine Immune Sciences is developing immune therapeutics.
Login
Username:

Password:


Related Headlines